Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Cristina Barrenetxea Lekue"'
Autor:
Phillip Scheinberg, Diego Cle, John Edwards, Valentina Giai, Marek Hus, Jin Seok Kim, Cristina Barrenetxea Lekue, Zsolt Nagy, Erfan Nur, Jens Panse, Yasutaka Ueda, Mustafa Nuri Yenerel, Anita Appius, Nadiesh Balachandran, Sammy Chebon, Brittany Gentile, Simon Buatois, Austin Kulasekararaj
Publikováno v:
HemaSphere, Vol 7, p e45540d8 (2023)
Externí odkaz:
https://doaj.org/article/2d2502a5b31c44548849194a5c1b9631
Autor:
Belen Navarro, Mario Spione, Cristina Barrenetxea Lekue, Juan-Manuel Sancho, Begoña Soler, Marco Bregni, Cristina Mombiedro, Jaime Pérez de Oteyza, Joan Alfons Soler Campos, Pier Luigi Zinzani, Silvina Grasso Cicala
Publikováno v:
European journal of haematologyREFERENCES. 104(5)
BACKGROUND AND OBJECTIVE: Few treatment options exist for patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) who fail first- and second-line therapies. Pixantrone is a novel aza-anthracenedione agent with reduced potential for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ac7162bf7da0453e32301eaa6de9490
https://pubmed.ncbi.nlm.nih.gov/31997425
https://pubmed.ncbi.nlm.nih.gov/31997425
Autor:
Silvina Grasso Cicala, Francesco d'Amore, Clara Alonso Caballero, Judit Jørgensen, Thomas Stauffer Larsen, Cristina Barrenetxea Lekue, Susana Herráez Rodríguez, Helle Toldbod, Sirpa Leppä, Irene Leal Martinez
Publikováno v:
Barrenetxea Lekue, C, Grasso Cicala, S, Leppä, S, Stauffer Larsen, T, Herráez Rodríguez, S, Alonso Caballero, C, Jørgensen, J M, Toldbod, H, Leal Martínez, I & D’Amore, F 2019, ' Pixantrone beyond monotherapy : a review ', Annals of Hematology, vol. 98, no. 9, pp. 2025-2033 . https://doi.org/10.1007/s00277-019-03749-0
Annals of Hematology
Annals of Hematology
Outcomes for patients with non-Hodgkin’s lymphoma (NHL) that proves refractory to treatment remain poor. Treatment of such patients is individualized and can include enrolment in a clinical trial of novel agents or use of one of a wide array of dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::660418f1ff8c4927ca50b28e0dde538f
https://findresearcher.sdu.dk:8443/ws/files/153162135/Pixantrone_beyond_monotherapy.pdf
https://findresearcher.sdu.dk:8443/ws/files/153162135/Pixantrone_beyond_monotherapy.pdf
Autor:
Antonia Rodriguez Izquierdo, Samuel Romero, Eduardo Ríos Herranz, Cristina Barrenetxea Lekue, Izaskun Ceberio, Luis Palomera, Antonio Gutierrez, Inmaculada Heras, R. Alonso, Joan Buch, Irene Garcia-Garcia, Joan Bargay, Narvaez Javier, Cecilia Carpio, Ramón García-Sanz, Manuel Espeso de Haro, Carmen Martinez
Publikováno v:
Blood. 132:2936-2936
Background: Nivolumab, an immune checkpoint inhibitor, has been tested in patients with classical Hodgkin lymphoma (cHL) who failed standard treatment options and has demonstrated remarkable activity with acceptable safety profile in clinical trials.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03d1d5e2766f9712ff67c2eb67db724d
https://doi.org/10.1182/blood-2018-99-115774
https://doi.org/10.1182/blood-2018-99-115774